Subcutaneous Immunoglobulin Therapy

What we do

Our Subcutaneous Immunoglobulin (SCIg) Therapy Service supports patients who require SCIg treatments.

This is a home-based patient self-administered therapy. Patients undergo training with a specialist nurse. SCIg therapy provides patients with treatment-lifestyle flexibility, empowering patients’ autonomy in self-management and improving their quality of life.

Who can use our service

Patients must meet one of the following National Blood Authority’s criteria for the clinical use of immunoglobulin in Australia to be approved for SCIg therapy:

• Primary immunodeficiency diseases with antibody deficiency
• Specific antibody deficiency
• Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)
• Secondary hypogammaglobulinaemia unrelated to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT)
• Chronic inflammatory demyelinating polyneuropathy (CIDP), (including IgG and IgA paraproteinaemic demyelinating neuropathies)

Find out more about SCIg on the National Blood Authority website.